EARLSDON PHARMA LTD

Company Registration Number:
14586363 (England and Wales)

Unaudited abridged accounts for the year ended 31 January 2026

Period of accounts

Start date: 01 February 2025

End date: 31 January 2026

EARLSDON PHARMA LTD

Contents of the Financial Statements

for the Period Ended 31 January 2026

Balance sheet
Notes

EARLSDON PHARMA LTD

Balance sheet

As at 31 January 2026


Notes
2026
2025


£
£
Fixed assets
Intangible assets: 3 592,756 640,618
Tangible assets: 4 37,414 47,440
Total fixed assets: 630,170 688,058
Current assets
Stocks: 104,520 109,250
Debtors: 5 115,550 147,170
Cash at bank and in hand: 474,197 275,721
Total current assets: 694,267 532,141
Creditors: amounts falling due within one year:   (476,372) (316,612)
Net current assets (liabilities): 217,895 215,529
Total assets less current liabilities: 848,065 903,587
Total net assets (liabilities): 848,065 903,587
Capital and reserves
Called up share capital: 100,000 100,000
Share premium account: 689,768 689,768
Profit and loss account: 58,297 113,819
Shareholders funds: 848,065 903,587

The notes form part of these financial statements

EARLSDON PHARMA LTD

Balance sheet statements

For the year ending 31 January 2026 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 01 October 2026
and signed on behalf of the board by:

Name: IMRAZ GUL ASHRAF
Status: Director

The notes form part of these financial statements

EARLSDON PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 January 2026

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

EARLSDON PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 January 2026

2. Employees

2026 2025
Average number of employees during the period 11 7

EARLSDON PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 January 2026

3. Intangible Assets

Total
Cost £
At 01 February 2025 736,342
At 31 January 2026 736,342
Amortisation
At 01 February 2025 95,724
Charge for year 47,862
At 31 January 2026 143,586
Net book value
At 31 January 2026 592,756
At 31 January 2025 640,618

EARLSDON PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 January 2026

4. Tangible Assets

Total
Cost £
At 01 February 2025 72,134
Additions 5,500
At 31 January 2026 77,634
Depreciation
At 01 February 2025 24,694
Charge for year 15,526
At 31 January 2026 40,220
Net book value
At 31 January 2026 37,414
At 31 January 2025 47,440

EARLSDON PHARMA LTD

Notes to the Financial Statements

for the Period Ended 31 January 2026

5. Debtors

2026 2025
££
Debtors due after more than one year: 115,550 147,170